Reengineering translational Science: The time is right

Science Translational Medicine

Volumn 3, Issue 90, 2011, Pages

  Collins, Francis S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LOSARTAN POTASSIUM; THALIDOMIDE;

AORTA DISSECTION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FINANCIAL MANAGEMENT; GENETIC ASSOCIATION; GENETIC ENGINEERING; HUMAN; HUMAN GENOME PROJECT; MEDICAL RESEARCH; MORNING SICKNESS; MULTIPLE MYELOMA; NATIONAL HEALTH ORGANIZATION; NONHUMAN; NOTE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DATABASE; TRANSLATIONAL RESEARCH; VALIDATION PROCESS; VIRTUAL REALITY; ARTICLE; MASS COMMUNICATION; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DIFFUSION OF INNOVATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); TRANSLATIONAL RESEARCH; UNITED STATES;

EID: 79960100831     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002747     Document Type: Note

References (63)

1. B. Munos, Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 (2009).
2. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, A. L. Schacht, How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
3. M. S. Brown, J. L. Goldstein, A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986).
4. J. Axelrod, L. G. Whitby, G. Hertting, Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science 133, 383-384 (1961).
5. R. P. Ahlquist, A study of the adrenotropic receptors. Am. J. Physiol. 153, 586-600 (1948).
6. A. Wlodawer, M. Miller, M. Jaskólski, B. K. Sathyanarayana, E. Baldwin, I. T. Weber, L. M. Selk, L. Clawson, J. Schneider, S. B. Kent, Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245, 616-621 (1989).
7. T. A. Manolio, Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166-176 (2010).
8. National Human Genome Research Institute, A Catalog of Published Genome-Wide Association Studies. http://www.genome.gov/gwastudies.
9. Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/omim/.
10. Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile 2010 (PhRMA, Washington, DC, 2011); available at http://www.phrma.org/sites/default/files/159/profile-2010-final.pdf.
11. D. Wilson, Drug firms face billions in losses in '11 as patents end. The New York Times (7 March 2011). http://www.nytimes.com/2011/03/07/business/ 07drug.html.
12. Ernst & Young, Beyond borders: Global biotechnology report 2010 (Ernst & Young, New York, 2010). http://www.ey.com/publication/vwluassets/ beyond-borders/$file/beyond-borders-2010.pdf.
13. F. S. Collins, M. Morgan, A. Patrinos, The Human Genome Project: Lessons from large-scale biology. Science 300, 286-290 (2003).
14. Battelle Technology Partnership Practice, Economic Impact of the Human Genome Project (Battelle, Columbus, OH, 2011). http://www.battelle.org/ publications/humangenomeproject.pdf.
15. E. Birney, J. A. Stamatoyannopoulos, A. Dutta, R. Guigó, T. R. Gingeras, E. H. Margulies, Z. Weng, M. Snyder, E. T. Dermitzakis, R. E. Thurman, M. S. Kuehn, C. M. Taylor, S. Neph, C. M. Koch, S. Asthana, A. Malhotra, I. Adzhubei, J. A. Greenbaum, R. M. Andrews, P. Flicek, P. J. Boyle, H. Cao, N. P. Carter, G. K. Clelland, S. Davis, N. Day, P. Dhami, S. C. Dillon, M. O. Dorschner, H. Fiegler, P. G. Giresi, J. Goldy, M. Hawrylycz, A. Haydock, R. Humbert, K. D. James, B. E. Johnson, E. M. Johnson, T. T. Frum, E. R. Rosenzweig, N. Karnani, K. Lee, G. C. Lefebvre, P. A. Navas, F. Neri, S. C. Parker, P. J. Sabo, R. Sandstrom, A. Shafer, D. Vetrie, M. Weaver, S. Wilcox, M. Yu, F. S. Collins, J. Dekker, J. D. Lieb, T. D. Tullius, G. E. Crawford, S. Sunyaev, W. S. Noble, I. Dunham, F. Denoeud, A. Reymond, P. Kapranov, J. Rozowsky, D. Zheng, R. Castelo, A. Frankish, J. Harrow, S. Ghosh, A. Sandelin, I. L. Hofacker, R. Baertsch, D. Keefe, S. Dike, J. Cheng, H. A. Hirsch, E. A. Sekinger, J. Lagarde, J. F. Abril, A. Shahab, C. Flamm, C. Fried, J. Hackermüller, J. Hertel, M. Lindemeyer, K. Missal, A. Tanzer, S. Washietl, J. Korbel, O. Emanuelsson, J. S. Pedersen, N. Holroyd, R. Taylor, D. Swarbreck, N. Matthews, M. C. Dickson, D. J. Thomas, M. T. Weirauch, J. Gilbert, J. Drenkow, I. Bell, X. Zhao, K. G. Srinivasan, W. K. Sung, H. S. Ooi, K. P. Chiu, S. Foissac, T. Alioto, M. Brent, L. Pachter, M. L. Tress, A. Valencia, S. W. Choo, C. Y. Choo, C. Ucla, C. Manzano, C. Wyss, E. Cheung, T. G. Clark, J. B. Brown, M. Ganesh, S. Patel, H. Tammana, J. Chrast, C. N. Henrichsen, C. Kai, J. Kawai, U. Nagalakshmi, J. Wu, Z. Lian, J. Lian, P. Newburger, X. Zhang, P. Bickel, J. S. Mattick, P. Carninci, Y. Hayashizaki, S. Weissman, T. Hubbard, R. M. Myers, J. Rogers, P. F. Stadler, T. M. Lowe, C. L. Wei, Y. Ruan, K. Struhl, M. Gerstein, S. E. Antonarakis, Y. Fu, E. D. Green, U. Karaöz, A. Siepel, J. Taylor, L. A. Liefer, K. A. Wetterstrand, P. J. Good, E. A. Feingold, M. S. Guyer, G. M. Cooper, G. Asimenos, C. N. Dewey, M. Hou, S. Nikolaev, J. I. Montoya-Burgos, A. Löytynoja, S. Whelan, F. Pardi, T. Massingham, H. Huang, N. R. Zhang, I. Holmes, J. C. Mullikin, A. Ureta-Vidal, B. Paten, M. Seringhaus, D. Church, K. Rosenbloom, W. J. Kent, E. A. Stone, S. Batzoglou, N. Goldman, R. C. Hardison, D. Haussler, W. Miller, A. Sidow, N. D. Trinklein, Z. D. Zhang, L. Barrera, R. Stuart, D. C. King, A. Ameur, S. Enroth, M. C. Bieda, J. Kim, A. A. Bhinge, N. Jiang, J. Liu, F. Yao, V. B. Vega, C. W. Lee, P. Ng, A. Shahab, A. Yang, Z. Moqtaderi, Z. Zhu, X. Xu, S. Squazzo, M. J. Oberley, D. Inman, M. A. Singer, T. A. Richmond, K. J. Munn, A. Rada-Iglesias, O. Wallerman, J. Komorowski, J. C. Fowler, P. Couttet, A. W. Bruce, O. M. Dovey, P. D. Ellis, C. F. Langford, D. A. Nix, G. Euskirchen, S. Hartman, A. E. Urban, P. Kraus, S. Van Calcar, N. Heintzman, T. H. Kim, K. Wang, C. Qu, G. Hon, R. Luna, C. K. Glass, M. G. Rosenfeld, S. F. Aldred, S. J. Cooper, A. Halees, J. M. Lin, H. P. Shulha, X. Zhang, M. Xu, J. N. Haidar, Y. Yu, Y. Ruan, V. R. Iyer, R. D. Green, C. Wadelius, P. J. Farnham, B. Ren, R. A. Harte, A. S. Hinrichs, H. Trumbower, H. Clawson, J. Hillman-Jackson, A. S. Zweig, K. Smith, A. Thakkapallayil, G. Barber, R. M. Kuhn, D. Karolchik, L. Armengol, C. P. Bird, P. I. de Bakker, A. D. Kern, N. Lopez-Bigas, J. D. Martin, B. E. Stranger, A. Woodroffe, E. Davydov, A. Dimas, E. Eyras, I. B. Hallgrímsdóttir, J. Huppert, M. C. Zody, G. R. Abecasis, X. Estivill, G. G. Bouffard, X. Guan, N. F. Hansen, J. R. Idol, V. V. Maduro, B. Maskeri, J. C. McDowell, M. Park, P. J. Thomas, A. C. Young, R. W. Blakesley, D. M. Muzny, E. Sodergren, D. A. Wheeler, K. C. Worley, H. Jiang, G. M. Weinstock, R. A. Gibbs, T. Graves, R. Fulton, E. R. Mardis, R. K. Wilson, M. Clamp, J. Cuff, S. Gnerre, D. B. Jaffe, J. L. Chang, K. Lindblad-Toh, E. S. Lander, M. Koriabine, M. Nefedov, K. Osoegawa, Y. Yoshinaga, B. Zhu, P. J. de Jong, ENCODE Project Consortium, NISC Comparative Sequencing Program, Baylor College of Medicine Human Genome Sequencing Center, Washington University Genome Sequencing Center, Broad Institute, Children's Hospital Oakland Research Institute, Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799-816 (2007).
16. The Genotype-Tissue Expression (GTEx) Project, http://www.genome.gov/ gtex/.
17. E. S. Lander, Initial impact of the sequencing of the human genome. Nature 470, 187-197 (2011).
18. J. C. Cohen, E. Boerwinkle, T. H. Mosley Jr., H. H. Hobbs, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
19. C. M. Dobson, Chemical space and biology. Nature 432, 824-828 (2004).
20. D. J. Newman, G. M. Cragg, Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461-477 (2007).
21. G. Schneider, Virtual screening: An endless staircase? Nat. Rev. Drug Discov. 9, 273-276 (2010).
22. P. Greaves, A. Williams, M. Eve, First dose of potential new medicines to humans: How animals help. Nat. Rev. Drug Discov. 3, 226-236 (2004).
23. S. J. Shukla, R. Huang, C. P. Austin, M. Xia, The future of toxicity testing: A focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov. Today 15, 997-1007 (2010).
24. F. S. Collins, G. M. Gray, J. R. Bucher, Toxicology. Transforming environmental health protection. Science 319, 906-907 (2008).
25. H. Inoue, S. Yamanaka, The use of induced pluripotent stem cells in drug development. Clin. Pharmacol. Ther. 89, 655-661 (2011).
26. D. G. Warnock, C. C. Peck, A roadmap for biomarker qualifi cation. Nat. Biotechnol. 28, 444-445 (2010).
27. The Biomarkers Consortium, http://www.biomarkersconsortium.org/.
28. M. de Jong, T. Maina, Of mice and humans: Are they the same? -Implications in cancer translational research. J. Nucl. Med. 51, 501-504 (2010).
29. H. Geerts, Of mice and men: Bridging the translational disconnect in CNS drug discovery. CNS Drugs 23, 915-926 (2009).
30. R. Weissleder, M. J. Pittet, Imaging in the era of molecular oncology. Nature 452, 580-589 (2008).
31. K. Lan, W. Jia, An integrated metabolomics and pharmacokinetics strategy for multi-component drugs evaluation. Curr. Drug Metab. 11, 105-114 (2010).
32. S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, P. R. Greipp, Eastern Cooperative Oncology Group, Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431-436 (2006).
33. B. S. Brooke, J. P. Habashi, D. P. Judge, N. Patel, B. Loeys, H. C. Dietz 3rd, Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Engl. J. Med. 358, 2787-2795 (2008).
34. R. Huang, N. Southall, Y. Wang, A. Yasgar, P. Shinn, A. Jadhav, D.-T. Nguyen, C. P. Austin, The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 3, 80ps16 (2011).
35. F. S. Collins, Mining for therapeutic gold. Nat. Rev. Drug Discov. 10, 397 (2011).
36. D. Jones, Adaptive trials receive boost. Nat. Rev. Drug Discov. 9, 345-348 (2010).
37. J. Woodcock, Chutes and ladders on the critical path: Comparative effectiveness, product value, and the use of biomarkers in drug development. Clin. Pharmacol. Ther. 86, 12-14 (2009).
38. J. Jia, F. Zhu, X. Ma, Z. Cao, Y. Li, Y. Z. Chen, Mechanisms of drug combinations: Interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111-128 (2009).
39. Food and Drug Administration, Draft Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination (FDA, Silver Spring, MD, 2010); available at http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm236669.pdf.
40. J. Woodcock, J. P. Griffin, R. E. Behrman, Development of novel combination therapies. N. Engl. J. Med. 364, 985-987 (2011).
41. A. D. Barker, C. C. Sigman, G. J. Kelloff, N. M. Hylton, D. A. Berry, L. J. Esserman, I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009).
42. L. Corey, G. J. Nabel, C. Dieffenbach, P. Gilbert, B. F. Haynes, M. Johnston, J. Kublin, H. C. Lane, G. Pantaleo, L. J. Picker, A. S. Fauci, HIV-1 vaccines and adaptive trial designs. Sci. Transl. Med. 3, 79ps13 (2011).
43. M. S. Lauer, F. S. Collins, Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research. JAMA 303, 2182-2183 (2010).
44. M. A. Hamburg, F. S. Collins, The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).
45. The NIH Common Fund, Regulatory Science, NIH. http://commonfund.nih.gov/ regulatoryscience.
46. FDA-NIH Joint Leadership Council Charter, FDA. http://www.fda.gov/ scienceresearch/specialtopics/regulatoryscience/ucm201654.htm.
47. FY 2012 NIH Budget Roll-out, NIH. http://www.nih.gov/about/director/ budgetrequest/fy2012budgetslides.pdf.
48. S. J. Steele, Working with the CTSA Consortium: What we bring to the table. Sci. Transl. Med. 2, 63mr5 (2010).
49. S. A. Wartman, Toward a virtuous cycle: The changing face of academic health centers. Acad. Med. 83, 797-799 (2008).
50. M. A. Fischl, D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, D. King, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 185-191 (1987).
51. A. J. Stevens, J. J. Jensen, K. Wyller, P. C. Kilgore, S. Chatterjee, M. L. Rohrbaugh, The role of public-sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364, 535-541 (2011).
52. FDA Approved Products Developed with Technologies from the NIH Intramural Research Program (1991-2009), NIH; available at http://www.ott.nih.gov/about- nih/fda-approved-products.aspx.
53. N. W. Barton, R. O. Brady, J. M. Dambrosia, A. M. Di Bisceglie, S. H. Doppelt, S. C. Hill, H. J. Mankin, G. J. Murray, R. I. Parker, C. E. Argoff, R. P. Grewal, K.-T. Yu, Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324, 1464-1470 (1991).
54. R. Schneerson, J. B. Robbins, J. C. Parke, Jr, C. Bell, J. J. Schlesselman, A. Sutton, Z. Wang, G. Schiffman, A. Karpas, J. Shiloach, Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide- tetanus toxoid conjugates. Infect. Immun. 52, 519-528 (1986).
55. B. S. Wilson, C. C. Finley, D. T. Lawson, R. D. Wolford, D. K. Eddington, W. M. Rabinowitz, Better speech recognition with cochlear implants. Nature 352, 236-238 (1991).
56. The Pharmacogenomics Knowledge Base. http://www.pharmgkb.org.
57. Literature analysis by R. Ranganathan and C. Woods.
58. Molecular Libraries Program. NIH, http://mli.nih.gov/mli.
59. Therapeutics for Rare and Neglected Diseases, NIH. http://trnd.nih.gov.
60. NIH Rapid Access to Interventional Development. http://commonfund.nih. gov/raid.
61. Office of Rare Diseases Research, NIH. http://rarediseases.info.nih.gov.
62. E. G. Nabel, On board with the Cures Acceleration Network. Sci. Transl. Med. 2, 32ed2 (2010).
63. Acknowledgments: I thank numerous colleagues for helpful comments on this essay, including C. Austin, T. Fauci, J. Goldstein, K. Hudson, E. Lander, S. Paul, L. Tabak, and H. Varmus. I also thank R. Ranganathan and C. Woods for the analysis included in Table 1 and R. Ranganathan and R. Kolberg for assistance in manuscript preparation.